0000904454-19-000517.txt : 20190621 0000904454-19-000517.hdr.sgml : 20190621 20190621165207 ACCESSION NUMBER: 0000904454-19-000517 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190621 DATE AS OF CHANGE: 20190621 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-89131 FILM NUMBER: 19912082 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Ginkgo Bioworks, Inc. CENTRAL INDEX KEY: 0001648827 IRS NUMBER: 263118890 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 27 DRYDOCK AVENUE, 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 877-422-5362 MAIL ADDRESS: STREET 1: 27 DRYDOCK AVENUE, 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 SC 13G 1 s13g_061119-synlogic.htm SCHEDULE 13G FOR SYNLOGIC, INC. BY GINKGO BIOWORKS, INC.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13G
Under the Securities Exchange Act of 1934
 
(Amendment No. ___)*
Synlogic, Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
87166L100
(CUSIP Number)
June 11, 2019
Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
o  Rule 13d-1(b)
 
x   Rule 13d-1(c)
 
o   Rule 13d-1(d)

*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).





CUSIP No. 87166L100


1
Name of Reporting Person:
 
Ginkgo Bioworks, Inc.
 
I.R.S. Identification No. of above Person (entities only) (voluntary)
 
  
2
Check the Appropriate Box if a Member of a Group
 
(a) ☐
(b) ☐
  
3
SEC USE ONLY
 
  
4
Citizenship or Place of Organization

Delaware
  

NUMBER OF
5
SOLE VOTING POWER
 
8,888,888*
SHARES
BENEFICIALLY
OWNED BY
6
SHARED VOTING POWER
0
 
EACH
REPORTING
PERSON
7
SOLE  DISPOSITIVE POWER
8,888,888*
 
WITH
8
SHARED DISPOSITIVE POWER
0
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED
 
8,888,888*
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
19.99% **
12
TYPE OF REPORTING PERSON
 
CO

* Includes 6,340,771 shares of Common Stock and 2,548,117 shares of Common Stock issuable upon exercise of Warrants.

** Based on 31,729,414 shares of Common Stock outstanding as of June 11, 2019, comprised of (i) 25,388,643 shares of Common Stock outstanding as of May 2, 2019, as reported in the Issuer’s Report on Form 10-Q for the period ended March 31, 2019 filed with the Securities and Exchange Commission on May 9, 2019 and (ii) 6,340,771 shares of Common Stock issued by the Issuer in a private placement on June 11, 2019 pursuant to which the Reporting Person acquired the securities reported herein, such 8,888,888 shares of Common Stock represent approximately 25.9% of the Common Stock outstanding, however the terms of the Warrants include a beneficial ownership limitation pursuant to which the Warrants are exercisable only to the extent that such exercise does not result in the Reporting Person’s beneficial ownership exceeding 19.99% of the Common Stock outstanding at any time.





2
CUSIP No. 87166L100


SCHEDULE 13G

Item 1(a)
Name of Issuer:  Synlogic, Inc.
Item 1(b)
Address of Issuer’s Principal Executive Offices:
 
301 Binney Street, Suite 402, Cambridge, MA  02142
 
Item 2(a)
Name of Person Filing:  Ginkgo Bioworks, Inc. (the “Reporting Person”)
Item 2(b)
Address of Principal Business Office, or if None, Residence:
 
27 Drydock Avenue, 8th Floor, Boston, MA  02210
 
Item 2(c)
Citizenship or Place of Organization:  Delaware
 
Item 2(d)
Title of Class of Securities:   Common Stock, $0.001 par value (the “Common Stock”)
Item 2(e)
CUSIP Number:  87166L100
Item 3
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is:   Not Applicable
Item 4
Ownership:
The information set forth in the cover page to this Schedule 13G is incorporated herein by reference thereto.
Item 5
Ownership of Five Percent or Less of the Class:  Not Applicable
 
Item 6
Ownership of More than Five Percent on Behalf of Another Person:  Not Applicable
   
Item 7
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:   Not Applicable 
 
Item 8
Identification and Classification of Members of the Group:  Not Applicable
 
Item 9
Notice of Dissolution of Group:  Not Applicable
Item 10
Certification:
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.
 





3
CUSIP No. 87166L100


SIGNATURE
 
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date:  June 19, 2019


 
GINKGO BIOWORKS, INC.
  
     
 
By:
/s/ Reshma Shetty
  
 
Name:
Reshma Shetty
  
 
Title:
Attorney-in-Fact
  





4